Michael B. Sawyer

Michael B. Sawyer

Auto-generated profile, based on publicly available information

Michael B. Sawyer

Cross Cancer Institute, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MCMichael P. Chu
Michael P. Chu
SGSunita Ghosh
Sunita Ghosh
CCCarole R. Chambers
Carole R. Chambers
NBNaveen Basappa
Naveen Basappa
CBCharles A. Butts
Charles A. Butts
MSMichael B. Sawyer
Michael B. Sawyer

8 December 2015 in British Journal of Cancer
Verified
Journal Article
Open access
ACAngela W Chan
Angela W Chan
PMPascal Mercier
Pascal Mercier
DSDaniel Schiller
Daniel Schiller
RBRobert Bailey
Robert Bailey
SRSarah Robbins
Sarah Robbins
DBDavid I Broadhurst
David I Broadhurst
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

17 April 2012 in British Journal of Cancer
Verified
Journal Article
Open access
CPC M M Prado
C M M Prado
TBT Bekaii-Saab
T Bekaii-Saab
LDL A Doyle
L A Doyle
SSS Shrestha
S Shrestha
SGS Ghosh
S Ghosh
MSM B Sawyer
M B Sawyer
Background: Methods: Results: Conclusion:

1 June 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MCMichael P. Chu
Michael P. Chu
JHJ. Randolph Hecht
J. Randolph Hecht
DSDennis Slamon
Dennis Slamon
ZWZev A. Wainberg
Zev A. Wainberg
YBYung-Jue Bang
Yung-Jue Bang
MSMichael B. Sawyer
Michael B. Sawyer
Prognosis of advanced or metastatic gastric cancer has remained consistently poor over time.1 Amplification or overexpression of human epidermal growth factor receptor 2 (ERBB2/HER2) occurs in 7% to 34% of gastric cancers, making trastuzumab, an anti-ERBB2/HER2 monoclonal antibody, a viable therapy for ERBB2/HER2-positive gastroesophageal cancer (GEC).2 The ToGA trial3 found an improvement in both progression-free survival (PFS) and overall survival (OS) when trastuzumab was combined with cisplatin and capecitabine or fluorouracil in comparison with the chemotherapy alone. The clinical superiority of a doublet chemotherapy plus a biologic drug is questionable, however, owing to nearly simultaneous reporting of improved outcomes of combined next-generation cytotoxic chemotherapies, such as oxaliplatin and capecitabine.4

5 July 2017 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
JHJessica J Hopkins
Jessica J Hopkins
MSMichael B Sawyer
Michael B Sawyer
Introduction: Body surface area dosing of chemotherapeutic agents is based on limited scientific data, and often results in unpredictable plasma drug levels. Cross-sectional computed tomography (CT) imaging provides an accurate measurement of lean mass. This review summarizes emerging roles of lean mass in predicting pharmacokinetics and drug toxicities in cancer patients. Areas covered: A concise review of body composition measurement with CT cross-sectional imaging and its relationship to drug pharmacokinetics and toxicities. A comprehensive review of the predictive value of low lean mass (sarcopenia) in dose-limiting toxicities is also included. Expert commentary: Drug dosing in medical oncology faces many challenges, including heterogeneous body composition profiles. The emerging role of sarcopenia in predicting lean mass may provide the tool needed to more accurately dose patients and prevent dose-limiting toxicities.

15 December 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
VDVanessa W Davis
Vanessa W Davis
DSDan Schiller
Dan Schiller
DEDean T Eurich
Dean T Eurich
MSMichael B Sawyer
Michael B Sawyer
Esophageal adenocarcinoma (EAC) often presents at a late, incurable stage, and mortality has increased substantially, due to an increase in incidence of EAC arising out of Barrett’s esophagus. When diagnosed early, however, the combination of surgery and adjuvant therapies is associated with high cure rates. Metabolomics provides a means for non- invasive screening of early tumor-associated perturbations in cellular metabolism.